A Phase 2 interventional study of Low Dose PRT042 nasal spray and median Dose PRT042 nasal spray in Major Depressive Disorder (MDD, sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd.. Completed at 15 sites in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.
Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 102nd largest by enrollment of the 174 interventional ones that give a count, is one of 23 that started in 2025, is one of 19 in phase 2, and was the 168th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 11–19
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Guo Wenbin · Sites in China
Ages 18–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 20 · Phase 4 19
First in 2004; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 120 across the 174 interventional studies, 240 across the 33 observational. Of the 77 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 207 have an industry lead sponsor. The 10 most frequent:
Sichuan Purity Pharmaceutical Technology Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Sichuan Purity Pharmaceutical Technology Co., Ltd. has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
21 of the studies in Depressive Disorder, Major with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04984512Phase 3Sunshine Lake Pharma Co., Ltd.The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | 2027-07 |
| NCT06913309Peking University Sixth HospitalClinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder | 2026-11-30 |
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT07873060Qilu Hospital of Shandong UniversityComparing 10 Hz rTMS and iTBS for Adolescent Depression | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 207 studies in Depressive Disorder, Major with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Low Dose PRT042 nasal spray
Drug: median Dose PRT042 nasal spray
Drug: high dose PRT042 nasal spray
Drug: placebo
two times a week, for 4 weeks
two times a week, for 4 weeks
two times a week, for 4 weeks
two times a week, for 4 weeks
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2)
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Change From Baseline in Montgomery Asberg Depression Rating Scale Total Score During Double-blind Phase
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Days 1 (4 hours postdose), 4, 8, 11, 15, 18, 22 and Day 25
Number of Participants who Achieved Response (≥50% decrease from baseline MADRS total score)Through the Double-blind Phase
Time frame: Days 1 (4 hours postdose),2, 4, 8, 11, 15, 18, 22 and Day 25
Number of Participants Who Achieved Remission (MADRS Total Score Less Than or Equal to [<=] 12) Through the Double-blind Phase
Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25
5. Change From Baseline in Clinical Global Impression- Severity of Suicidality-Revised (CGI-SS-R) During Double-blind Phase
CGI-SS-R was derived from the Clinical Global Impression Severity Scale (CGI-S), a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants). A higher score indicates a more severe condition and a reduction in score indicates improvement (that is, lower severity of suicidality).
Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25
Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1) Through Double-blind Phase
Time frame: up to Day 25
Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) Scale Total Score During Double-blind Phase
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.
Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and Day 25
8. Change From Baseline in Beck Hopelessness Scale (BHS) Total Score During Double-blind Phase
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.
Time frame: Baseline, Days 8 ,15 and 25
Change From Baseline in Beck Scale for Suicide Ideation -Chinese Version (BSI-CV) Total Score During Double-blind Phase
BSI-CV is a self-reported measure with 19 items, scored on a 3-point scale (0 to 2). The final score ranges from 0 to 38, with higher scores indicating a greater likelihood of suicide.
Time frame: Baseline, Days 8 ,15 and 25
Number of Participants With Treatment Emergent Adverse Events (TEAEs)、Vital Signs Abnormalities、Abnormal Electrocardiogram (ECG) Values et al: DB Treatment Phase
Time frame: up to Day 25
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])
Time frame: up to Day 25
Maximum Plasma Concentration [Cmax]
Time frame: up to Day 25
plasma elimination half-life [T1/2]
Time frame: up to Day 25
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Apr 2026, 10 months.
Of 99 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 10 months is below that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Purity Pharmaceutical Technology Co., Ltd.